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ABSTRACT
Introduction Cirrhotic patients with portal hypertension 
can suffer from variceal bleeding or refractory ascites and 
can benefit from a transjugular intrahepatic portosystemic 
shunt (TIPS). Post- TIPS hepatic encephalopathy (HE) is a 
common (20%–54%) and often severe complication. A 
prophylactic strategy is lacking.
Methods and analysis The Prevention of hepatic 
Encephalopathy by Administration of Rifaximin and 
Lactulose in patients with liver cirrhosis undergoing 
placement of a TIPS (PEARL) trial, is a multicentre 
randomised, double blind, placebo controlled trial. Patients 
undergoing covered TIPS placement are prescribed 
either rifaximin 550 mg two times per day and lactulose 
25 mL two times per day (starting dose) or placebo 
550 mg two times per day and lactulose 25 mL two times 
per day from 72 hours before and until 3 months after 
TIPS placement. Primary endpoint is the development 
of overt HE (OHE) within 3 months (according to West 
Haven criteria). Secondary endpoints include 90- day 
mortality; development of a second episode of OHE; time 
to development of episode(s) of OHE; development of 
minimal HE; molecular changes in peripheral and portal 
blood samples; quality of life and cost- effectiveness. The 
total sample size is 238 patients and recruitment period 
is 3 years in six hospitals in the Netherlands and one in 
Belgium.
Ethics and dissemination This study protocol was 
approved in the Netherlands by the Medical Research 
Ethics Committee of the Academic Medical Centre, 
Amsterdam (2018-332), in Belgium by the Ethics 
Committee Research UZ/KU Leuven (S62577) and 
competent authorities. This study will be conducted in 
accordance with Good Clinical Practice guidelines and 
the principles of the Declaration of Helsinki. Study results 
will be submitted for publication in a peer- reviewed 
journal.
Trial registration numbers  ClinicalTrials. gov 
(NCT04073290) and EudraCT database (2018-004323-
37).
INTRODUCTION
Portal hypertension and TIPS
Liver cirrhosis is the most common cause 
of portal hypertension (PH). Complica-
tions of PH include (refractory) ascites and 
oesophageal or gastric variceal bleedings. 
These complications are severe and result in 
hospital admissions and decreased survival. 
Moreover, cirrhotic patients undergo phys-
ical deterioration due to undernutrition and 
muscle wasting and are physically frail.1
A transjugular intrahepatic portosystemic 
shunt (TIPS) reduces PH, by decompression 
of the portal system through an artificial shunt 
from a intrahepatic portal vein to a hepatic 
vein. TIPS can be considered as therapy 
for refractory ascites and variceal bleeding. 
TIPS treatment for refractory ascites has 
a response rate, defined as improvement 
of ascites, of up to 85%.2 3 A meta- analysis 
showed improved survival of cirrhotic 
patients receiving a (uncovered) TIPS, with a 
decreased risk of refractory ascites and hepa-
torenal syndrome.4 However, these patients 
have an increased risk of hepatic encepha-
lopathy (HE). Improvement of survival was 
confirmed in a recent randomised controlled 
trial (RCT): 1- year transplant- free survival was 
significantly higher in patients who received 
TIPS (93%) compared with patients who 
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were treated with large volume paracentesis (LVP) and 
albumin infusion (52%) and suggested that TIPS should 
be the first line of treatment of refractory ascites.5
Another consequence of PH is the development 
of gastric or oesophageal varices. One- third of the 
patients who are diagnosed with liver cirrhosis and are 
compensated have oesophageal varices, and in patients 
presenting with ascites, this is the case in up to 60%.6 
Seventy per cent of all upper gastrointestinal bleeding 
episodes in patients with cirrhosis are caused by variceal 
bleeding.6 In patients with multiple bleeds, high risk 
of treatment failure (recurrence of variceal bleed), or 
increased mortality risk (Child Pugh C (<11 points) liver 
cirrhosis), a TIPS is a highly effective intervention (94%) 
to control bleeding.7 Hence, TIPS is a very effective inter-
vention to treat complications of PH.2 3 7 However, also 
these patients are at risk for post- TIPS HE.8–10
Hepatic encephalopathy
HE is a common complication in patients with liver 
cirrhosis and is associated with profound loss of quality 
of life. HE is a brain dysfunction caused by liver insuffi-
ciency and/or portosystemic shunting; it manifests as a 
wide spectrum of neurological or psychiatric abnormal-
ities ranging from subclinical alterations to coma.11 HE 
is classified using the West- Haven criteria: minimal HE 
(MHE), covert HE (grade I) or overt HE (OHE, grades 
II–IV).12 MHE is subtle cognitive impairment that is diffi-
cult to detect clinically and only by psychometric testing. 
The psychometric hepatic encephalopathy score (PHES) 
and simplified one min animal naming test (S- ANT1) are 
two validated instruments to measure MHE.13 14 PHES 
exists of a line tracing test, digit symbol test, serial dotting 
test and a number connection test.13 S- ANT1 is a 1 min 
test in which patients name as many animals as possible. 
The outcome of this test was validated to score MHE.14 
OHE presents with a varying severity and symptoms as 
disorientation, motor dysfunctions, abnormalities in 
behaviour, intellectual functions and consciousness. 
Thirty to forty- five per cent of patients with liver cirrhosis 
develop OHE during the course of their disease.15 HE 
leads to a prolonged duration of hospital admissions, an 
increased number of primary care contacts, an impaired 
quality of life and increased mortality.11 16–19
Treatment and prevention of OHE
The initial treatment of OHE is non- absorbable disaccha-
rides like lactulose.11 The dosing of lactulose should be 
initiated with 25 mL of lactulose every 12 hours and the 
dose should be titrated to achieve two soft or loose bowel 
movements per day.11 The working mechanism of lact-
ulose is not fully understood, but it is assumed that the 
prebiotic effects and acidifying nature of lactulose have 
an additional benefit beyond the laxative effect.20 21
There is currently no treatment registered for primary 
prevention of HE. Secondary prevention of HE can be 
achieved by combination therapy of lactulose with rifax-
imin, a poorly absorbed antibiotic. In the Netherlands, 
rifaximin has been approved since 2016 and will be reim-
bursed only to prevent a third (or following) episode of 
OHE.22
Post-TIPS HE
HE is a common and often severe complication after TIPS 
placement. Incidence of new onset OHE or worsening 
of MHE after TIPS is approximately 20%–54%.7–10 Risk 
factors for post- TIPS HE are mainly described for uncov-
ered stents in retrospective studies. Extensive prospective 
evidence is lacking and little evidence is available for 
covered stents. Prior HE episodes, increased CP score 
and increased age are possible risk factors, but there is 
no consensus about the exact limits.23 In patients with 
variceal bleeding, a TIPS diameter of 8 mm can decrease 
the incidence of post- TIPS HE compared with 10 mm.24
The International Club of Ascites published their 
sixth position paper on PH in 2015.25 Both this group 
of international experts in PH as well as the European 
Association for the Study of the Liver (EASL)/American 
Association for the Study of Liver Diseases (AASLD) prac-
tice guidelines have prioritised studies on treatment and 
prevention of (post- TIPS) HE on the research agenda 
because of the lack of strong evidence regarding primary 
prevention.11 25 Besides a missing strategy to prevent 
HE after TIPS placement, it is currently not possible to 
predict whether patients will suffer from post- TIPS HE. 
Moreover, possible biomarkers currently are lacking.
Prevention of post-TIPS HE
An RCT, Riggio et al, showed that rifaximin (1200 mg/
day) alone or lactitol (60 mL/day) alone did not prevent 
HE after TIPS placement.26 It is unclear whether polytet-
rafluoroethylene covered stents or bare metal stents were 
used. Although not fully published yet, a more recent 
RCT, Bureau 2019, does show a positive effect of rifax-
imin on post- TIPS HE. In this trial, rifaximin 1200 mg/
day was started 15 days before TIPS placement until 6 
months post- TIPS.
The combination of rifaximin and lactulose has never 
been tested to prevent post- TIPS HE. This might prove 
to be a more effective strategy, as it has been shown to 
be effective in the prevention of recurrent HE and is 
current standard of care.27 In this particular RCT—both 
in patients with and without TIPS—a reduction of 58% in 
episodes of HE was realised, and a 50% reduction in the 
risk of hospitalisation was achieved.27 Two other double- 
blind RCTs confirmed that combination of lactulose and 
rifaximin decreased the risk of HE.28 29 Apart from inhibi-
tion of intestinal bacterial RNA synthesis, effects of rifax-
imin on intestinal cells can be observed within 24 hours. 
Intestinal barrier function is improved, and there is an 
upregulation of enzymes involved in detoxification.30 31 
Based on the effectiveness of lactulose and rifaximin, we 
hypothesise that the combination of lactulose and rifax-
imin will reduce the number of patients with post- TIPS 
HE.
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To assess the incidence of post- TIPS OHE within the first 
3 months after prophylactic administration of lactulose 
and rifaximin versus lactulose and placebo in patients 
who undergo covered TIPS placement.
Secondary objectives
To assess:
1. Ninety- day mortality.
2. Transplant- free survival.
3. The development of a second episode of OHE within 
the first 3 months after covered TIPS placement.
4. The development of OHE between 3 and 12 months 
after covered TIPS placement.
5. Time to development OHE or MHE episode(s).
6. The change in PHES and S- ANT1 test during the 
study: at time points week 4, week 12 and week 52, 
compared with baseline.
7. The change in Liver Frailty Index score at week 12 
and week 52, compared with baseline.
8. Differences in molecular composition of peripheral/
portal blood samples at TIPS placement.
9. Differences in molecular composition of peripher-
al blood samples at baseline, compared with day 10 
post- TIPS, week 4, week 12 and week 52.
10. Quality of life.
11. Costs and cost- effectiveness.
METHODS AND ANALYSIS
Trial design
The Prevention of hepatic Encephalopathy by Adminis-
tration of Rifaximin and Lactulose in patients with liver 
cirrhosis undergoing placement of a TIPS (PEARL) 
trial, is a multicentre randomised, double blind, placebo 
controlled trial. Six academic hospitals from the Neth-
erlands and one academic hospital from Belgium 
will be involved in the recruitment. In order to mini-
mise burden for the study subjects, this trial has been 
designed in such a way that visits for patients are the 
same as standard of care. A flowchart of the trial design 
is found in figure 1.
Eligibility criteria
Inclusion criteria
All of the following criteria must be met in order to be 
eligible for participation in this trial:
1. Elective- covered TIPS placement for refractory ascites 
(a) and/or recurrent variceal bleeding (b):
a. Recurrent tense ascites and at least one of the fol-
lowing criteria:
 – Not responding to the maximal dose of diuretics 
(400 mg spironolactone and 160 mg furosemide).
 – Kidney insufficiency (creatinine >135 μmol/L) 
induced by diuretics.
 – Electrolyte disturbances (sodium <125 mmol/L, 
potassium >5.5 mmol/L) induced by diuretics.
 – Not tolerating higher dose of diuretics (eg, 
because of subjective side effects like muscle 
cramps).
b. (Recurrent) variceal bleeding, not responsive to 
treatment with endoscopic band ligation and/or 
beta- blockers, with a high risk of failure of endo-
scopic treatment:
 – Patients with a variceal bleeding and Child- Pugh 
C (10–13 points) cirrhosis or
 – Patients with a variceal bleeding, Child- Pugh B 
and an active bleeding during endoscopy.
2. Age ≥18 years.
3. Confirmed liver cirrhosis as documented by liver bi-
opsy, elastography (eg, Fibroscan) or combination of 
usual radiological and biochemical criteria.
4. Signed informed consent.
Exclusion criteria
1. Any absolute contraindications for TIPS placement:
 – History of HE grades II–IV without precipitating 
factor (such as dehydration, variceal bleeding, SBP 
or other infection).
 – Heart failure New York Heart Association ≥grade 3.
 – Hepatocellular carcinoma (multifocal or large or 
centrally located).
 – Systemic infection/sepsis.
 – Severe pulmonary hypertension.
 – Unrelieved bile duct obstruction.
 – Technically not feasible.
 – Poor liver function (Model for End- stage Liver Dis-
ease (MELD) score >20).
2. Use of ciclosporin (124- fold higher systemic expo-
sure rifaximin).32
3. Life- threatening variceal bleeding with emergency 
TIPS placement that cannot be delayed for 72 hours.
4. Age >80 years.
5. Non- cirrhotic PH.
6. Portal vein thrombosis (main trunk).
7. HIV.
8. Current or recent (<3 months) use of rifaximin.
9. Overt neurologic diseases such as Alzheimer’s dis-
ease, Parkinson’s disease.
10. Pregnant or breastfeeding women.
Randomisation and concealment of allocation
After the screening visit, eligible study subjects will be 
stratified for MELD score <10 and >10. Study subjects 
are stratified randomised to the treatment or placebo 
in a 1:1 ratio. Randomisation with random blocks of 
sizes 4, 6 or 8 is performed by Castor Electronic Data 
Capture (Ciwit B.V., The Netherlands) in an automated 
way and sent to the local clinical trial pharmacy. Neither 
the treating physician nor the patient is aware of the 
randomisation result. Deblinding is possible in the 
case standard of care that might be withheld (see safety 
paragraph).
by copyright.










astroenterol: first published as 10.1136/bm






4 de Wit K, et al. BMJ Open Gastro 2020;7:e000531. doi:10.1136/bmjgast-2020-000531
Open access 
Intervention
Rifaximin 550 mg two times per day will be prescribed, 
in combination with a starting dose of 25 mL lactulose 
two times per day and further dependent on the amount 
of daily bowel movements, with the objective of two soft 
stools per day. In the case of a study subject already being 
treated with lactulose, that dose will be used. Interven-
tion will start 72 hours before TIPS placement and will 
last till 3 months after TIPS placement. The control 
group will receive placebo in combination with lactulose 
(as described above).
In the event of lactulose- related diarrhoea, dosage will 
be lowered to 10 mL two times a day. If diarrhoea persists: 
dosage is lowered to 5 mL two times a day. Once subjects 
have no diarrhoea anymore, dosage can be increased, 
with the objective to achieve two soft stools a day.
Outcome measures and study procedures
Primary outcome
The development of OHE within 3 months after covered 
TIPS placement is determined by the West Haven criteria.
Figure 1 Flowchart of the Prevention of hepatic Encephalopathy by Administration of Rifaximin and Lactulose in patients with 
liver cirrhosis undergoing placement of a TIPS (PEARL) trial.
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Secondary outcomes
Ninety- day mortality; development of a second episode 
of OHE within the first 3 months; development of OHE 
in the period between 3 and 12 months after covered 
TIPS placement; development of MHE between covered 
TIPS placement and 12 months after placement; time to 
development of OHE or MHE episodes; increase in the 
PHES, S- ANT1 score and LFI compared with baseline. 
Difference in the composition of portal blood samples, 
drawn at TIPS placement. TIPS placement data will be 
recorded. Furthermore, quality of life will be assessed 
by the Liver Disease Symptom Index V.2.0 (LDSI V.2.0) 
and EQ- 5D- 5L questionnaires. Costs will include costs of 
healthcare, productivity loss due to sick leave from work 
and out- of- pocket expenses.
Assessment schedule
A detailed assessment schedule is found in table 1.
HE assessment
HE will be assessed by West Haven criteria during all study 
visits. Additionally, HE is assessed by PHES and S- ANT1 at 
baseline, week 4, week 12 and week 52.
Frailty assessment
Liver Frailty Index test will be performed at baseline, 
week 12 and week 52.





TIPS Day 10 W4 W12 W26 W52
Window (days) max - 21 ±4     ±7 ±7 ±7 ±7 ±7
Eligibility assessments                   
Informed consent X                 
Inclusion/exclusion criteria X                 
Medical history 
+concomitant medication
X                 
Study medication           
Assessments                   
Physical examination* X X     X X X X X
Liver frailty index   X         X   X
Assessment of hepatic 
encephalopathy by West 
Haven criteria
X X     X X X X X
Assessment of hepatic 
encephalopathy by PHES 
and S- ANT1
  X       X X   X
Assessment of quality of 
life†
  X         X   X
Economic evaluation 
questionnaires‡
  X         X   X
Assessment of adverse 
events
      X X X X X X
Assessment of compliance 
and concomitant 
medication
      X X X X X X
Laboratory tests§ X X     X X X   X
Storage of peripheral blood 
and/or portal (*) vein blood
  X     X*     X   X
Storage of stool sample   X   X     X   X
Storage of saliva samples   X   X     X   X
Radiological assessment 
and flow measurement
X       X   X   X
NB: Visit day 7 might be the same as the day of start study medication.
*Height and weight, vital signs, including pulse rate, blood pressure, respiration rate and temperature, signs of ascites or oedema.
†EQ- 5D- 5L questionnaire and LDSI 2.0 questionnaire.
‡Adapted version of the Productivity Cost Questionnaire and Medical Consumption Questionnaire.
§Clinical chemistry: sodium, potassium, serum creatinine, glucose, alanine aminotransferase, aspartate aminotransferase, total and direct bilirubin, 
alkaline phosphatase, gamma- GT, C reactive protein, albumin, ammonia. Coagulation: international normalised ratio, PT. haematology: haematocrit, 
haemoglobin.
PHES, Psychometric Hepatic Encephalopathy Score; S- ANT1, simplified one min animal naming test.
by copyright.










astroenterol: first published as 10.1136/bm






6 de Wit K, et al. BMJ Open Gastro 2020;7:e000531. doi:10.1136/bmjgast-2020-000531
Open access 
TIPS placement data
The following data of TIPS placement will be recorded: 
intravenous antibiotic prophylaxis, method of anaes-
thesia, per procedural medication, mean ventilation 
pressure, TIPS placement technique, length of puncture 
canal, type of covered stent (Viatorr or Viatorr Controlled 
Expansion), length, diameter and dilatation of this stent, 
duration of the procedure, visualised collaterals, pressure 
measurements, embolisation and registration of possible 
complication(s).
Quality of life and economic evaluation questionnaires
Quality of life questionnaires are evaluated by EQ- 5D- 5L 
and LDSI V.2.0 at baseline, week 12 and week 52. 
Economic evaluation questionnaires to assess healthcare 
used and productivity losses are handed out as well at 
these time points.
Peripheral and portal blood samples
As shown in table 1, peripheral and portal blood samples 
will be taken from study subjects at several time points. 
Patients will be requested to fast 12 hours before blood 
withdrawal in order to avoid interference with, for 
example, dietary components in the analysis. Samples of 
peripheral blood at baseline will be compared with the 
samples at week 12 and week 52. Samples of peripheral 
blood (4 hours - 5 min before TIPS placement) will be 
compared with portal blood samples. Portal samples will 
be withdrawn directly after TIPS placement using a cath-
eter. When there are clinical signs that a reintervention 
of the TIPS is inevitable, additional portal and peripheral 
blood samples will be withdrawn. Additional sampling of 
portal blood can only occur with a maximum of three 
times during the first 3 months. In the case that reinter-
vention is necessary after 3 months, another two addi-
tional times of sampling are possible in the study period 
between 3 and 12 months after TIPS placement.
Untargeted metabolomics will be used to study differ-
ences in peripheral and portal blood samples as well to 
study differences in peripheral blood samples from the 
different time points. Moreover, lipidomics and small 
molecule analyses will be performed, all using liquid 
chromatography with tandem mass spectrometry. A more 
targeted approach is dependent on the results of these 
experiments.
Saliva and stool samples
For two ancillary studies, saliva and stool samples are 
collected for microbiome analyses in some participating 
centres (due to logistical reasons and a smaller sample 
size) at baseline, day 0, week 12 and week 52.
Statistical considerations
Sample size
The incidence of post- TIPS OHE is 20%–54% in interna-
tional studies.7–10 To determine the incidence of new onset 
or worsening HE in our own population, we performed 
a retrospective analysis of the last 16 years of patients 
undergoing TIPS placement.33 This study revealed that 
approximately 33% of the patients suffered from new or 
worsening of existing HE within 30 days after TIPS place-
ment. Between 30 and 90 days after TIPS placement, 17% 
still had HE. Actual percentages might be higher due to 
the retrospective nature of the study. Reduction of HE is 
achieved in 58% of the patients.27 However, due to selec-
tion bias, we estimate that in our study population. 50% 
reduction is realistic. The calculation of the sample size 
(nQuery Advisor V.7.0) was done for a χ2 test. Assuming 
that the effect of rifaximin and lactulose is a 50% reduc-
tion of HE, incidence of HE is expected to drop from 
33% to 16.5%. With a two- sided 5% alpha, power of 80%, 
a total of 107 study subjects are needed in both groups. 
With an estimated dropout of 10%, a total of 119 study 
subjects are needed in the intervention group and 119 
study subjects in the control group.
Analysis of outcome measures
A comprehensive statistical analysis plan (SAP) will be 
provided separately. Data will be analysed according to 
the intention to treat principle. Descriptive methods will 
be used to assess quality of data, homogeneity of treat-
ment groups and endpoints. A p value <0.05 is consid-
ered statistically significant. A brief outline is given in the 
next paragraph.
Primary outcome measurement
The primary outcome, development of OHE within 
3 months after TIPS placement determined by the West 
Haven criteria, will be compared between the interven-
tion and placebo group. Percentage differences with 
corresponding 95% CI will be reported as absolute 
improvement in percentages .
Secondary outcomes
Secondary outcomes will be analysed using either a 
t- test or Mann- Whitney U test for continuous data or a 
χ2 test for categorical data, as appropriate. Kaplan- Meier 
curves will be used to determine transplant- free survival. 
Kaplan- Meier curves will be used to determine the length 
of time for the subjects to reach the primary or secondary 
endpoint with regards to OHE. Censoring will be applied 
in analysis for liver transplantation or death by any cause. 
When censoring is applied, Cox proportional hazards 
model will be used. Comparison of peripheral and 
portal blood samples at TIPS placement will be analysed 
using a Wilcoxon signed rank test. Repeatedly measured 
endpoints will be analysed with mixed models, for the 
time point(s) they are measured (see table 1).
Economic evaluation
On the condition that the outcomes of this trial show 
beneficial results, a cost- effectiveness analysis (CEA), 
cost- utility analysis (CUA) and budget impact anal-
ysis (BIA) will be performed. Costs per patient without 
post- TIPS HE and the costs per quality- adjusted life year 
(QALY) will be used as primary economic outcomes. The 
CEA will estimate costs per additional patient without 
post- TIPS HE, offset against cost savings associated with 
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reduced incidence of post- TIPS HE by the use of rifax-
imin and lactulose for a short- term horizon (12 months). 
The CUA will estimate costs per additional QALY, with a 
horizon of 5 years. Analyses for the short- term horizon 
will be based on the empirical data from this trial. 
Observed differences in QALYs as well as resource use/
costs will be extrapolated to 5 years evaluating medium- 
term consequences. A longer horizon is not reasonable, 
since patients with end- stage liver cirrhosis have a poor 
long- term survival or will be transplanted after further 
progression of disease. Resource use during admission(s) 
will be assessed by case report form, complemented with 
the institute for Medical Technology Assessment Medical 
Consumption Questionnaire, Productivity Costs Ques-
tionnaire and patients’ health records during follow- up. 
To estimate unit costs for observed volumes of resource 
use, Dutch reference prices will be used. Health state util-
ities to estimate QALYs will be derived from EQ- 5D- 5L 
measurements at baseline, after 12 weeks of treatment 
and 9 months after cessation of rifaximin and lactulose. 
Finally, a BIA from a governmental and health insurer 
perspective will be performed, describing the financial 
consequences of prophylactic use of rifaximin and lactu-
lose and reduced number of hospital admissions for the 
extramural drugs budget respectively budget for special-
ised healthcare. The BIA will be performed in accor-
dance to the Dutch guideline for economic evaluations 
in healthcare, using the international accepted Interna-
tional Society for Pharmacoeconomics and Outcomes 
Research (ISPOR) principles.
Missing data
All efforts will be made to collect all data for each study 
subject to minimise missing data points. In the case of 
missing data, a multiple imputation approach will be 
applied, to be further detailed in the SAP.
Training and monitoring
Study staff members at participating sites are trained 
during an initiation visit to ensure that study procedures 
are carried out uniformly. The study is monitored by 
the Clinical Research Unit of the Amsterdam Univer-
sity Medical Centres. A full monitoring plan is available. 
Multiple site visits will take place for source data verifica-
tion and to verify adherence to the study protocol and its 
procedures.
Safety
Both investigational medicinal products used in this 
trial are safe and effective for (cirrhotic) patients and 
widely used. Known side effects of lactulose are abdom-
inal bloating and diarrhoea. These side effects are 
highly dosage dependent. Lactulose should therefore 
be initially administered two times per day 25 mL, or in 
case of a study subject already is being treated with lact-
ulose, that dose will be used to minimise side effects. If 
lactulose- related side effects occur, a step- down approach 
is in place to minimise these unwanted side effects, as 
described in the intervention paragraph.
In the case that OHE grade 3 (somnolent but respon-
sive to verbal stimuli) occurs for the first time, patients 
will be treated with standard care (eg, increase of lactu-
lose), as add- on to the study medication.
In the case that OHE grade 4 (coma) occurs, study medi-
cation will be temporarily discontinued and restarted as 
soon as possible after recovery of the HE episode.
In the case that a patient develops a second episode 
of OHE, allocation will be deblinded since patients will 
otherwise might be withheld from standard of care.
ETHICS AND DISSEMINATION
Ethical considerations
The study protocol was peer- reviewed by external 
reviewers during the grant application. In the Nether-
lands, the study protocol was reviewed and approved by 
the Medical Research Ethics Committee of the Academic 
Medical Centre, Amsterdam (2018-332#B2019406) 
and competent authority The Central Committee on 
Research involving Human Subjects (NL68205.018.18). 
In Belgium, this study was reviewed and approved 
by the Ethics Committee Research UZ/KU Leuven 
(S62577) and competent authority The Federal Agency 
for Medicines and Health Products (U89922A). This 
study will be conducted in accordance with Good 
Clinical Practice guidelines and the principles of the 
Declaration of Helsinki. This study is registered in  Clin-
icalTrials. gov (NCT04073290) and EudraCT database 
(2018-004323-37).
Dissemination
Results of this RCT will be submitted for presentation 
at (inter)national congresses and publication in a peer- 
reviewed journal. The coordinating investigator will 
prepare the manuscript and authorship is determined by 
the publication policy as stated in the study protocol. A 
lay summary of the study results will be made available 
through the website of the funder, the Netherlands Organ-
isation for Health Research and Development (ZonMw). 
This summary will also be published in the magazine and 
website of the Dutch Liver Patients Association.
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